Research Partnership publishes new patient Living with Atopic Dermatitis (EU) 2019 report
Living with Atopic Dermatitis (AD) is a new quantitative study conducted amongst 403 adults living with the disease and 141 caregivers of children with AD in France, Germany, Italy, Spain and UK.
AD is a common, chronic inflammatory skin disease that is characterised by intense itching and recurrent eczematous lesions and is estimated to affect 20% of children and 3% of adults worldwide. Until a few years ago, AD treatments were mainly limited to topical corticosteroids and systemic immunosuppressants, however a greater understanding of how AD develops has lead to the launch of new treatments (PDE-4 inhibitor, dupilumab) as well as a more robust pipeline.
The report enables pharmaceutical companies developing products in AD to gain a deeper understanding of how patients come to be diagnosed with AD and how it impacts their day-to-day lives physically, emotionally and socially. It also explores patient attitudes and perceptions towards treatment and the healthcare professionals managing their condition as well as identifying the types of support patients seek at key stages of their journey.
Head of Living with, Mariel Metcalfe commented, “Atopic Dermatitis can exert a major physical and emotional burden not only on the patient but also their caregivers. This report will provide comprehensive, quantitative insights into patient behaviours and perceptions, as well as their feelings and unmet needs at key stages of their journey living with AD.”
Living with AD (EU) is just one in a series of reports offering comprehensive insight into the chronic disease patient journey from pre-diagnosis to stabilisation. The Living with Atopic Dermatitis - AD (US), Crohn’s (EU & US), Diabetes (LATAM), Lupus - SLE (EU & US), Non-alcoholic Steatohepatitis - NASH (EU & US), Psoriasis – PsO (EU), Psoriatic arthritis - PsA (EU), Rheumatoid Arthritis – RA (US, EU, Japan & Canada) and Ulcerative Colitis -UC (EU & US) reports are published and available to purchase. Living with ankylosing spondylitis & nr-axSpA (EU & US) will be published in June 2019.
Sign up to receive Rapport
Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research. Sign up here »